XBIO:NASDAQXenetic Biosciences, Inc. Analysis
Data as of 2026-09-14 - not real-time
$3.90
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Xenetic Biosciences, Inc. is priced at $3.90 and its moving averages line up in bullish order, the shorter sitting above the longer. It has gained 52.9% over the past 30 days. RSI sits at 53.9, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at $3.16 up to resistance at $4.94.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Revenue is growing at 12.0% on a -75.9% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 64.4%, a beta of 1.93 and a maximum drawdown of 80.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Revenue is growing at 12.0% on a -75.9% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 64.4%, a beta of 1.93 and a maximum drawdown of 80.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Top Market Events
The only question Iowa is asking is should it be hard to raise taxesExpanded collaborative research initiatives reinforce the Company's long-term DNase development strategyOngoing...Yahoo Finance1monXenetic Biosciences: Q2 Earnings SnapshotFRAMINGHAM, Mass.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 2.84
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 2.84
- 30-day volatility of 64.4%
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Negative profit margin of -75.9%
- Negative return on equity of -47.0%
- Revenue growth of +12.0%
Key Metrics & Analysis
Financial Health
Revenue Growth12.00%
Profit Margin-75.91%
P/E Ratio-5.9
ROE-47.04%
ROA-26.80%
P/B Ratio1.2
Op. Cash Flow$-2312795
Free Cash Flow$-1174761
Industry P/E29.5
Technical Analysis
TrendBullish
RSI53.9
Support$3.16
Resistance$4.94
MA 20$3.90
MA 50$3.25
MA 200$2.84
MACDBearish
VolumeIncreasing
Fear & Greed Index90.18
Valuation
GradeFair
TypeBlend
Risk Assessment
Beta1.93
Volatility64.45%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.